公开(公告)号：US06183779B2

公开(公告)日：2001-02-06

申请号：US09273692

申请日：1999-03-22

Applicant: Aomar Ouali ,  Abul Kalam Azad

Inventor： Aomar Ouali ,  Abul Kalam Azad

IPC: A61K922

CPC classification number: A61K9/2081 ,  A61K9/209 ,  A61K9/5084 ,  Y10S514/951 ,  Y10S514/97

Abstract: A pharmaceutical composition is provided for the oral administration of an NSAID and a prostaglandin. The composition is a solid dosage form wherein the NSAID is enterically coated and the prostaglandin is present along with an effective stabilizing amount of a prostaglandin stabilizing agent such as hydroxypropyl methylcellulose or polyvinylpyrrolidone. Exemplary dosage forms are bilayer tablets in which the prostaglandin is misoprostol and the NSAID is diclofenac, piroxicam, or a pharmaceutically acceptable salt thereof. Methods for using the composition to treat NSAID-responsive conditions, disorders and diseases are provided as well.

Abstract translation: 提供了用于口服NSAID和前列腺素的药物组合物。 该组合物是固体剂型，其中NSAID是肠溶包衣的，并且前列腺素与有效稳定量的前列腺素稳定剂如羟丙基甲基纤维素或聚乙烯吡咯烷酮一起存在。 示例性剂型是其中前列腺素是米索前列醇和NSAID是双氯芬酸，吡罗昔康或其药学上可接受的盐的双层片剂。 还提供了使用该组合物治疗NSAID反应性病症，疾病和疾病的方法。

公开(公告)号：US06287600B1

公开(公告)日：2001-09-11

申请号：US09528550

申请日：2000-03-20

Applicant: Aomar Ouali ,  Abul Kalam Azad

Inventor： Aomar Ouali ,  Abul Kalam Azad

IPC: A61K916

CPC classification number: A61K9/2081 ,  A61K9/209 ,  A61K9/5084 ,  Y10S514/951 ,  Y10S514/97

Abstract: A pharmaceutical composition is provided for the oral administration of an NSAlD and a prostaglandin. The composition is a solid dosage form wherein the NSAID is enterically coated and the prostaglandin is present along with an effective stabilizing amount of a prostaglandin stabilizing agent such as hydroxypropyl methylcellulose or polyvinylpyrrolidone. Exemplary dosage forms are bilayer tablets in which the prostaglandin is misoprostol and the NSAID is diclofenac, piroxicam, or a pharmaceutically acceptable salt thereof. Methods for using the composition to treat NSAID-responsive conditions, disorders and diseases are provided as well.

Abstract translation: 提供用于口服NSA1D和前列腺素的药物组合物。 该组合物是固体剂型，其中NSAID是肠溶包衣的，并且前列腺素与有效稳定量的前列腺素稳定剂如羟丙基甲基纤维素或聚乙烯吡咯烷酮一起存在。 示例性剂型是其中前列腺素是米索前列醇和NSAID是双氯芬酸，吡罗昔康或其药学上可接受的盐的双层片剂。 还提供了使用该组合物治疗NSAID反应性病症，疾病和疾病的方法。

公开(公告)号：US5807577A

公开(公告)日：1998-09-15

申请号：US562057

申请日：1995-11-22

Applicant: Aomar Ouali

Inventor： Aomar Ouali

IPC: A61K9/00 ,  A61K9/20 ,  A61K9/46

CPC classification number: A61K9/0007 ,  A61K9/0056 ,  A61K9/2068 ,  Y10S514/819

Abstract: There is provided an improved, fast-melting solid dosage form which readily disintegrates when placed in the mouth. The solid dosage form preferably being a tablet comprising the following primary ingredients whose proportions are calculated as weight percent on the total weight of the tablet: (a) from about 30 to 50 weight percent, of a pharmaceutically acceptable active ingredient component; (b) an effervescent couple consisting of about 3 to 5 weight percent of an effervescence base about 3 to 5 weight percent of an effervescence acid suitable for achieving a gas evolving reaction with the effervescence base upon being contacted with an aqueous solution such as saliva; (c) about 40 to 50 weight percent of a pharmaceutically acceptable starch as a bulking and disintegrating agent; (d) about 3 to 5 weight percent of a tablet lubricant. Additionally, the tablet may comprise flavoring agents. The tablet is formed of granules of a mixture of the active ingredient component, the effervescence base, and the starch, admixed to a powderous blend of the remaining ingredients, subsequently compressed in tablet form. Also provided is a method of making the solid dosage form of the present invention.

Abstract translation: 提供了一种改进的，快速熔化的固体剂型，其在置于口中时容易崩解。 固体剂型优选为片剂，其包含以下主要成分，其比例以片剂总重量的重量百分数计算：（a）约30至50重量％的药学上可接受的活性成分组分; （b）泡腾对，其由约3至5重量％的泡腾碱组成，约3至5重量％的泡腾酸，其适于在与水溶液如唾液接触时实现与泡腾碱的气体放出反应; （c）约40至50重量％的作为膨胀和崩解剂的药学上可接受的淀粉; （d）约3至5重量％的片剂润滑剂。 此外，片剂可以包含调味剂。 片剂由活性成分组分，泡腾基质和淀粉的混合物的颗粒形成，与剩余成分的粉末混合物混合，随后以片剂形式压制。 还提供了制备本发明的固体剂型的方法。

公开(公告)号：US06414037B1

公开(公告)日：2002-07-02

申请号：US09430337

申请日：1999-10-29

Applicant: John M. Pezzuto ,  Richard C. Moon ,  Mei-Shiang Jang ,  Aomar Ouali ,  Shengzhao Lin ,  Karla Slowing Barillas

Inventor： John M. Pezzuto ,  Richard C. Moon ,  Mei-Shiang Jang ,  Aomar Ouali ,  Shengzhao Lin ,  Karla Slowing Barillas

IPC: A61K3105

CPC classification number: A61K31/7034 ,  A23L33/105 ,  A61K8/347 ,  A61K8/60 ,  A61K9/0014 ,  A61K9/0019 ,  A61K9/1075 ,  A61K31/05 ,  A61K47/10 ,  A61K47/14 ,  A61K47/36 ,  A61K47/549 ,  A61Q19/08 ,  B82Y5/00

Abstract: A method is provided for preventing or treating skin conditions, disorders or diseases, such as may be associated with or caused by inflammation, sun damage or natural aging. The method involves administration, preferably topical administration, of an active agent selected from the group consisting of resveratrol, pharmacologically acceptable salts, esters, amides, prodrugs and analogs thereof, and combinations of any of the foregoing. Pharmaceutical formulations for use in conjunction with the aforementioned method are provided as well.

Abstract translation: 提供了一种用于预防或治疗皮肤病症，疾病或疾病的方法，例如可能与炎症，阳光损伤或自然衰老相关或引起。 该方法包括给药，优选局部给药，选自白藜芦醇，其药理学上可接受的盐，酯，酰胺，前药和类似物，以及上述任何一种的组合的活性剂。 还提供了与上述方法结合使用的药物制剂。

公开(公告)号：US5807578A

公开(公告)日：1998-09-15

申请号：US752026

申请日：1996-11-19

Applicant: Tabare R. Acosta-Cuello ,  Aomar Ouali

Inventor： Tabare R. Acosta-Cuello ,  Aomar Ouali

IPC: A61J3/10 ,  A61K9/00 ,  A61K9/20 ,  A61K9/46

CPC classification number: A61K9/0007 ,  A61K9/0056 ,  A61K9/2068 ,  Y10S514/819

Abstract: Provided is an improved, fast-melting solid dosage form which readily disintegrates when placed in the mouth. The solid dosage form preferably being a tablet comprising the following primary ingredients whose proportions are calculated as weight percent on the total weight of the tablet: (a) from about 30 to 50 weight percent, of a pharmaceutically acceptable active ingredient component; (b) an effervescent couple consisting of about 2 to 5 weight percent of an effervescence base about 2 to 5 weight percent of an effervescence acid suitable for achieving a gas evolving reaction with the effervescence base upon being contacted with an aqueous solution such as saliva; (c) about 35 to 50 weight percent of a pharmaceutically acceptable starch as a bulking and disintegrating agent; (d) about 0.04 to 1 weight percent of a starch degrading enzyme; and (e) about 2 to 5 weight percent of a tablet lubricant. Additionally, the tablet may comprise flavoring agents. The tablet is formed of granules of a mixture of the active ingredient component, the effervescence base, and the starch, admixed to a powderous blend of the remaining ingredients, subsequently compressed in tablet form. Also provided is a method of making the solid dosage form of the present invention.

Abstract translation: 提供了一种改进的，快速熔化的固体剂型，其在置于口中时容易崩解。 固体剂型优选为片剂，其包含以下主要成分，其比例以片剂总重量的重量百分数计算：（a）约30至50重量％的药学上可接受的活性成分组分; （b）由约2至5重量％的泡腾基质组成的泡腾对，其中约2至5重量％的泡腾酸适用于在与水溶液如唾液接触时实现与泡腾碱的气体放出反应; （c）约35至50重量％的作为膨胀和崩解剂的药学上可接受的淀粉; （d）约0.04-1重量％的淀粉降解酶; 和（e）约2至5重量％的片剂润滑剂。 此外，片剂可以包含调味剂。 片剂由活性成分组分，泡腾基质和淀粉的混合物的颗粒形成，与剩余成分的粉末混合物混合，随后以片剂形式压制。 还提供了制备本发明的固体剂型的方法。